NIH PAR · NIDA · R61, R33
PAR-27-053: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This notice of funding opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-25-305 "Research Project Grant (Parent R01 Clinical Trial Required)" or its subsequent reissue).
- NOFO number
- PAR-27-053
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Aug 31, 2026
- Opens
- —
- Expires
- Jun 17, 2028
PAR-27-053 due dates
6 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| November 02, 2026 | November 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 19, 2027 | February 19, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 17, 2027 | June 17, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 20, 2027 | October 20, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 22, 2028 | February 22, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 16, 2028 | June 16, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
Funded projects
NIH RePORTER lists no awards under PAR-27-053 in FY2022–FY2026. Awards usually appear a few months after the first review cycle.
Participating institutes
2 NIH institutes and offices take applications under PAR-27-053. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- none
Related notices
NIH lists no related notices for PAR-27-053 yet.
Award terms
- Application types allowed
- New Resubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed 500,000. For the R33 phase, budgets are not limited, but need to reflect the actual needs of the proposed project.
- Project period
- The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-23-157.
Other open NOFOs for R61, R33
- RFA-DA-27-016HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)NIDA · next due Feb 10, 2027
- RFA-MH-27-125Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)NIMH · next due Nov 9, 2026
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
- RFA-DC-27-004BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Clinical Trial Not Allowed)NIDCD · next due Feb 11, 2027
- PAR-25-158Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)NIAAA · next due Oct 19, 2026
- PAR-25-269NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.